Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-495 / KeyImPaCT in advanced non-small cell lung cancer
2017-003134-85Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Oct 2018; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-003134-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003134-85.